type 2 diabetes
Conditions
Interventions
A:Isulin pump
B:xagliptin
Sponsors
Nanjing First Hospital, Nanjing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. voluntary to attend this study signed the informed consent, comply with the requirements of this study; 2. between 18 75 years of age; 3. according to the who standards, the subjects should be diagnosed as type 2 diabetes; 4. the subjects agreed to maintain the original diet exercise habits throughout the study period; 5. the weight was stable during the last 12 weeks before the screening, weight change range (+ / - 5%); 6. fasting serum c-peptide>=1 ng/ml (333 pmol/l or higher).
Exclusion criteria
Exclusion criteria: 1. the probabl basic diseases which may obstruct this study,such as active malignancy, cardiomyopathy, cirrhosis or chronic lung disease; 2. using incretin therapy now or during the past 6 months,such as dpp-4 glp-1; 3. pregnancy, breast-feeding,or not using enough contraception(enough refers to the intrauterine device, oral contraceptives, prevent measures). 4.the history of human immunodeficiency virus (hiv). 5.severe autoimmune diseases such as lupus. 6.using the intravenous hormone therapy. 7.patiens accepted other drugs during the past 1 month. 8.impaired liver function,the alt is 2.5 times of theper limit. 9.start long-term dialysis and/or renal transplantation, and/or serum creatinine is 1.3 times greater than that of theper limit. 10.a history of drug abuse alcohol dependence in the past 5 years. 11.recurrent hypoglycemic events. 12.acute vascular events (heart or stroke)during the past two months before randomization. heart disease: decompented heart failure (type nyha ? ?), unstable angina, a heart attack in the past 12 months. 13.allergic to the drugs or related products (insulin, metal),or local induration in insulin injection site. 14.poor adherence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| function of islet beta cell; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glucagon;free fatty acid;8-iso-PGF2 alpha;TNF-alpha;GLP-1;glucose fluctuation; | — |
Countries
China
Contacts
Public ContactJianhua Ma
Outcome results
None listed